Tag #Anti-Fungal Resistance

What are the underlying causes of the slow development of new antifungal drugs and diagnostics, and what are the consequences of this delay?

The lack of new antifungal drugs and diagnostic tools is particularly problematic for immunocompromised individuals (e.g., those undergoing chemotherapy, HIV-positive, or organ transplant recipients), who experience significantly higher rates of fungal infections. This shortage is a global health crisis, exacerbated by the slow pace of innovation in this area.